Results
Type
Country of origin
Qualifications

Osimertinib | compare suppliers & send inquiries for free

Here you will find a list of producers, manufacturers and traders of Osimertinib. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
Apino Pharma Co., Ltd.

MOQ: 1 kg
Type: Producer
Origin: China
China
MSN Labs.

MOQ: 0 kg
Type: Producer
Origin: India
India
JINLAN Pharm-Drugs Technology Co., Ltd.

MOQ: 1 g
Type: Producer
Origin: China
China
R&S Chemicals

MOQ: 10 g
Type: Producer
Origin: United States
United States
Alembic Pharma


Type: Producer
Origin: India
India
Suzhou Bichal Biological Technology

MOQ: 10 g
Type: Producer
Origin: China
China
Shandong Octagon Chemicals Limited

MOQ: 10 g
Type: Trader
Origin: China
China

Looking for Osimertinib 1421373-65-0?

API | Excipient name:
Osimertinib 
Synonyms:
Mereletinib  
Cas Number:
1421373-65-0 
DrugBank number:
DB09330 
Unique Ingredient Identifier:
3C06JJ0Z2O

About Osimertinib

What makes Osimertinib unique? Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy.

Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.

Check who is selling Osimertinib in the overview above.

Osimertinib manufacturers | traders | suppliers
We have 7 companies offering Osimertinib from 3 different countries.

Get in contact with the supplier of your choice:

  • Apino Pharma Co., Ltd. from China
  • MSN Labs. from India
  • JINLAN Pharm-Drugs Technology Co., Ltd. from China
  • R&S Chemicals from United States
  • Shandong Octagon Chemicals Limited from China
  • Suzhou Bichal Biological Technology from China
  • Alembic Pharma from India

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.